Image

Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension

Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension

Recruiting
18-90 years
All
Phase N/A

Powered by AI

Overview

The proposed study aims to evaluate optic nerve head blood flow and microcirculation in patients with idiopathic intracranial hypertension. For this purpose, optic nerve head blood flow will be examined in patients with IIH before and after therapy and additionally compared with healthy age- and sex-matched control subjects. In addition, other parameters will be measured, in particular retinal blood flow, retinal oxygen saturation and retinal neurovascular coupling.

Description

Idiopathic intracranial hypertension (IIH) is a neuroophthalmological disease, characterized by an increased intracranial pressure (ICP) without an identifiable causative factor. If not properly treated and carefully monitored the disease can even lead to irreversible severe or complete loss of vision or severe irreversible visual field defects, respectively. Given this clinical urgency, precise diagnostic tools become essential for timely decision making.

Laser Speckle Flowgraphy (LSFG) is a non-invasive, in-vivo imaging method, which quantitatively estimates blood flow in the optic nerve head, the choroid, the retina and the iris. LSFG has a low procedural complexity, obtains precise and reproducible measurements and is therefore suitable to assess ocular perfusion.

The proposed study aims to evaluate optic nerve head blood flow and microcirculation in patients with idiopathic intracranial hypertension. For this purpose, optic nerve head blood flow will be examined in patients with IIH before and after therapy and additionally compared with healthy age- and sex-matched control subjects. In addition, other parameters will be measured, in particular retinal blood flow, retinal oxygen saturation and retinal neurovascular coupling.

Eligibility

Inclusion criteria for patients with idiopathic intracranial hypertension

  • Men and Women aged ≥ 18 years
  • Signed informed consent
  • Newly diagnosed idiopathic intracranial hypertension or relapse of idiopathic intracranial hypertension
  • Non-Smokers

Inclusion criteria for healthy age- and sex-matched control subjects

  • Men and Women aged ≥ 18 years
  • Signed informed consent
  • Normal ophthalmic findings, unless the investigator considers an abnormality to be clinically irrelevant
  • Normal findings in the medical history, unless the investigator considers an abnormality to be clinically irrelevant
  • Non-Smokers

Exclusion criteria for patients with idiopathic intracranial hypertension and healthy age- and sex-matched control subjects:

  • Blood donation in the three weeks preceding the study
  • Symptoms of a clinically relevant illness in the three weeks preceding the study
  • Ocular inflammation or infection within the last 3 months
  • History or family history of epilepsy
  • Diabetes mellitus type 1 or type 2
  • History or known presence of other cerebral vascular diseases (e.g.: arteriovenous malformation, aneurysm, major artery stenosis or occlusion)
  • History or known presence of intracranial infections (e.g.: meningitis)
  • History or known presence of other neurological diseases (e.g.: brain tumor, hydrocephalus, degenerative diseases)
  • Patients receiving corticosteroids or immunosuppressant therapy
  • Pregnant or breast-feeding women
  • Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception

Study details
    Idiopathic Intracranial Hypertension

NCT06545981

Medical University of Vienna

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.